Platinum Compounds clinical trials
Its developmentBy 5 companies, company by company5 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Platinum Compounds is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Platinum Compounds studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2009 | 1 |
| 2014 | 1 |
| 2016 | 3 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 21
Sun Yat-sen University (2) · China Medical University, China (2) · Peking Union Medical College Hospital (2) · Memorial Sloan Kettering Cancer Center (1) · Fudan University (1) · Bristol-Myers Squibb (1) · Shanghai Gynecologic Oncology Group (1) · Eli Lilly and Company (1)
Often tested with
Tested in the same studies.
Etoposide (3) · Bevacizumab (3) · Paclitaxel (3) · Pemetrexed (3) · Gemcitabine (3) · Anlotinib (3) · Tislelizumab (3) · Apatinib (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Platinum Compounds is the comparator. A study of two new drugs counts under both.
- 1Ifebemtinib · InxMed (Shanghai) Co., Ltd. · next primary completion Sep 2028
- 1Garsorasib · InxMed (Shanghai) Co., Ltd. · next primary completion Sep 2028
Reaching primary completion within a year · 4
Studies that test Platinum Compounds.
- Dec 2026A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECPhase 2 · Tianjin Medical University Cancer Institute and Hospital
- Apr 2027QLS5132 Combination Therapy in Advanced Solid TumorsPhase 1/2 · Qilu Pharmaceutical Co., Ltd.
- Jun 2027A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersPhase 1 · Memorial Sloan Kettering Cancer Center
- Nov 2027A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Phase 2 · Peking Union Medical College Hospital
Studies
Open first, then newest update. How each study uses Platinum Compounds is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07510594Written as Benmelstobart+ Anlotinib+ Platinum + EtoposideHow we know
- Durvalumab as Consolidation for Patients LS-SCLCRecruitingPhase 2Qian ChuNCT07055581Written as Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenanceHow we know
- QLS5132 Combination Therapy in Advanced Solid TumorsNot yet recruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07453394Written as QLS5132; Platinum; BevacizumabHow we know
- Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingPhase 2China Medical University, ChinaNCT07376499Written as PlatinumHow we know
- HS-10502 Combination Treatment in Patients With Advanced Solid TumorsRecruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06769425Written as HS-10502 + Platinum + BevacizumabHow we know
- Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingPhase 4China Medical University, ChinaNCT06951841Written as PlatinumHow we know
- Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type AdenocarcinomaNot yet recruitingPhase 3Women's Hospital School Of Medicine Zhejiang UniversityNCT06870565Written as paclitaxel and platinumHow we know
- First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLCRecruitingPhase 2Xiaorong DongNCT05745350Written as Pembrolizumab, Plinabulin plus Etoposide and PlatinumHow we know
- DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.RecruitingPhase 4Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06820255Written as Platinum + GemcitabineHow we know
- Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLCRecruitingPhase 2Hunan Province Tumor HospitalNCT05296278Written as IBI-323 combined with bevacizumab plus PlatinumHow we know
- A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingPhase 2Peking Union Medical College HospitalNCT06142617Written as Pembrolizumab, pemetrexed, platinumHow we know
- Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain MetastaticRecruitingNot applicableHebei Medical University Fourth HospitalNCT06056115Written as Tislelizumab,PlatinumHow we know
- Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLCNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT05782426Written as paclitaxel polymeric micelles for injectionHow we know
- Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical CancerRecruitingPhase 3Fourth Affiliated Hospital of Guangxi Medical UniversityNCT05735145Written as paclitaxel combined with platinumHow we know
- A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT03567642Written as PlatinumHow we know
- Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung CancerActive, not recruitingNot applicableFudan UniversityNCT05407155Written as bevacizumab plus nab-paclitaxel and platinumHow we know
- Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung CancerCompletedPhase 3Sun Yat-sen UniversityNCT01951482Written as Pemetrexed/PlatinumHow we know
- Trial of BMS-986012 in Combination With Platinum and EtoposideCompletedPhase 1Bristol-Myers SquibbNCT02815592Written as PlatinumHow we know
- Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLCStatus unknownPhase 2Sichuan Cancer Hospital and Research InstituteNCT05394233Written as Tislelizumab Combined With Bevacizumab and Platinum Plus PemetrexedHow we know
- Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung CancerStatus unknownPhase 3Sun Yat-sen UniversityNCT01951469Written as Gefitinib and Pemetrexed/platinumHow we know
See all 26 studies that test Platinum Compounds →
Given beside what is tested · 20 — Platinum Compounds is usual care or a partner of the new treatment
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingPhase 1National Cancer Institute (NCI)NCT03816345Written as Platinum CompoundHow we know
- A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07532902Written as PlatinumHow we know
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyRecruitingPhase 2SWOG Cancer Research NetworkNCT06769126Written as Platinum CompoundHow we know
- JSKN033 Combination Therapy in Subjects With Advanced Cervical CancerNot yet recruitingPhase 2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT07497074Written as PlatinumHow we know
- Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033Not yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07097948Written as PlatinumHow we know
- Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingPhase 2Fudan UniversityNCT06355037Written as Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinumHow we know
- Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 TrialRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06256237Written as PlatinumHow we know
- Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.Not yet recruitingPhase 2Obstetrics & Gynecology Hospital of Fudan UniversityNCT06128460Written as PlatinumHow we know
- Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 TrialRecruitingPhase 3Sun Yat-sen UniversityNCT04502641Written as PlatinumHow we know
- Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer PatientsRecruitingPhase 3Chinese Academy of Medical SciencesNCT03731442Written as PlatinumHow we know
- A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsCompletedPhase 1/2TakedaNCT04420884Written as PlatinumHow we know
- Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung CancerCompletedPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06648200Written as PlatinumHow we know
- JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLCActive, not recruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT06969027Written as PlatinumHow we know
- Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLCCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT03607539Written as PlatinumHow we know
- Inosine Reverse Chemo Resistance in Triple Negative Breast CancerCompletedPhase 2Fudan UniversityNCT06355024Written as Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinumHow we know
- A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCActive, not recruitingPhase 2Biotheus Inc.NCT05844150Written as PlatinumHow we know
- A Study of Apatinib Treatment in for Advanced Ovarian CancerStatus unknownPhase 2The People's Hospital of LeshanNCT03393507Written as Taxus + platinumHow we know
- Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard TreatmentStatus unknownPhase 2The First Affiliated Hospital of Anhui Medical UniversityNCT03224221Written as fluorouracil and platinumHow we know
- Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast CancerStatus unknownPhase 2Xinjiang Medical UniversityNCT02489409Written as PlatinumHow we know
- An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) PatientsCompletedPhase 2Oncozyme Pharma Inc.NCT01844791Written as PlatinumHow we know
As the comparator · 5 — what is tested is compared with Platinum Compounds
- A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C MutationRecruitingPhase 3InxMed (Shanghai) Co., Ltd.NCT07174908Written as anti-PD-1 monoclonal antibody in combination with platinum and pemetrexedHow we know
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingPhase 2UNICANCERNCT02299999Written as Platinum based chemotherapiesHow we know
- Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLCStatus unknownPhase 2Tang-Du HospitalNCT04338620Written as albumin-bound paclitaxel and platinumHow we know
- Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLCCompletedPhase 2/3Fudan UniversityNCT01769066Written as Pemetrexed/PlatinumHow we know
- Randomized Gefitinib TrialCompletedPhase 3Fondazione Humanitas per la RicercaNCT00807066Written as PlatinumHow we know
Codes
What other systems call Platinum Compounds · ClinicalTrials.gg INT008608
- MeSH (NLM) D017671Platinum CompoundsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D017671 | Platinum Compounds | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.